Kamada (KMDA) Non-Current Debt (2015 - 2025)

Kamada's (KMDA) quarterly Non-Current Debt came in at $2.1 million in Q1 2025, down 80.81% on a QoQ basis from $10.7 million in Q2 2023.

Kamada (KMDA) Non-Current Debt (2015 - 2025) Analysis & Trends

Kamada (KMDA) has 10 years of Non-Current Debt data on file, last reported at $2.1 million in Q1 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $2.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.1 million (changed N/A YoY) and the FY2022 annual result came in at $13.0 million, down 25.53% from the prior year.
Non-Current Debt retreated to $2.1 million in Q1 2025, from $10.7 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $17.4 million in Q4 2021 to a low of $5000.0 in Q2 2021.
A 4-year average of $7.5 million and a median of $6.4 million in 2023 frame the typical range for Non-Current Debt.
Annual changes were most pronounced in 2022 — Non-Current Debt surged 303600.0% — and 2023, when it sank 99.93%.
Tracing KMDA's Non-Current Debt over 4 years: stood at $17.4 million in 2021, then dropped by 25.53% to $13.0 million in 2022, then dropped by 17.14% to $10.7 million in 2023, then plunged by 80.81% to $2.1 million in 2025.
The last three Non-Current Debt figures came in at $2.1 million (Q1 2025), $10.7 million (Q2 2023), and $11852.0 (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-8.44 Bn
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	12.09 Bn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	27.73 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	-
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	11.61 Bn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	-
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	3.85 Bn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	130.00 Mn
10	Kamada	458.29 Mn	428.82 Mn	22.47 Mn	-

Download Data